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We describe the synthesis of C8-alkynyl adenine pyranonucleosides 4, 5, and
8-phenylethynyl-adenine (II), via Sonogashira cross-coupling reaction under microwave
irradiation. Compounds 4e and IIwere less cytostatic than 5-fluorouracil (almost an order
of magnitude) against murine leukemia (L1210) and human cervix carcinoma (HeLa) cells,
while the same compounds proved to be more active than 5-fluorouracil against human
lymphocyte (CEM) cells.
Keywords: Sonogashira coupling reaction, 8-bromoadenine, N6-benzoyladenine pyranonucleosides, microwave
irradiation, cytotoxic activity
Introduction
Synthetic nucleoside analogs with modified nucleobase moieties are of considerable importance
in the search for promising lead candidates endowed with antiviral, anticancer, and antibacterial
activities (Herdewijn, 2008; Manta et al., 2014). Among them, a number of purine and pyrimi-
dine substituted nucleoside derivatives exhibited activity in both solid tumors and hematological
malignancies, behaving as antimetabolites, competing with physiological nucleosides, and conse-
quently, interacting with a large number of intracellular targets to induce cytotoxicity (Hatse et al.,
1999).
Alkynyl-modified nucleosides and especially pyrimidine derivatives substituted atC5 and purine
derivatives substituted atC8, have been shown to possess interesting biological properties (Lin et al.,
1985; Meneni et al., 2007; Lee et al., 2009; Vivet-Boudou et al., 2011). Some representative examples
include 5-ethynyl-2′-deoxyuridine, which exhibited antiproliferative activity against human breast
cancer cells, exceeding that of cisplatin and 5-fluorouracil, while 5-bromoethynyluridine demon-
strated significant anti-HCV properties (Escuret et al., 2005; Meneni et al., 2007). Although, little
effort has been made toward the synthesis of C8-modified purine nucleosides, in some cases, inter-
esting biological properties have been reported, such as some 8-alkynyl adenosines, which proved
to be very selective ligands for the A3 adenosine receptor subtype behaving as adenosine antago-
nists (Volpini et al., 2001) and various C8-modified 2′-deoxy adenosines, which induced delayed
chain termination in vitro and showed moderate anti HIV-1 activity in cell culture (Vivet-Boudou
et al., 2011).
Dimopoulou et al. C8-Alkynyl adenine pyranonucleosides
Considering all the progress made toward this direction, we
have recently embarked on the synthesis of C5-substituted uracil
and cytosine glucopyranonucleosides bearing a variety of alkyne
substituents, such as linear alkyl chains and aromatic rings substi-
tuted with linear and branched alkyl groups (Dimopoulou et al.,
2013), which effectively inhibited the proliferation of a variety of
tumor cell lines and they also proved as some of the most potent
inhibitors of the active site of glycogen phosphorylase (Kantsadi
et al., 2012). Among these agents, the C5-phenylethynyluracil
pyranonucleoside showed appreciable cytotoxic activity (IC50 of
5.2–6.2µM), comparable to 5-fluorouracil (Dimopoulou et al.,
2013).
As a continuation of our studies on the synthesis of base-
modified pyranonucleosides and considering the interesting bio-
logical properties of substituted purines, it was speculated that
the introduction of alkynyl modifications at the 8-position of
either adenine pyranonucleosides or even adenine itself, could
possibly lead to more efficacious therapeutic agents. This conju-
gation appeared to us as a challenge and the first biological results
confirmed our hypothesis.
Experimental (General Methods)
Melting points were recorded in a Mel-Temp apparatus and are
uncorrected. Thin layer chromatography (TLC) was performed
on Merck precoated 60F254 plates. Reactions were monitored
by TLC on silica gel, with detection by UV light (254 nm) or
by charring with sulfuric acid. Flash column chromatography
was performed using silica gel (240–400 mesh, Merck). 1H and
13C NMR spectra were obtained at room temperature with a
Bruker 300 spectrometer at 300 and 75.5MHz, respectively using
chloroform-d (CDCl3) and dimethylsulfoxide-d6 (DMSO-d6)
with internal tetramethylsilane (TMS). The 1H assignments were
based on 1H -1H COSY experiments executed using standard
Varian software. Chemical shifts (δ) were given in ppm mea-
sured downfield from TMS, and spin-spin coupling constants
are in Hz. Mass spectra were obtained on a ThermoQuest Finni-
gan AQA Mass Spectrometer (electrospray ionization). Optical
rotations were measured using an Autopol I polarimeter and
UV-Vis spectra were recorded on a PG T70 UV-VIS spectrom-
eter. Acetonitrile (CH3CN) was distilled from calcium hydride
and stored over 3Å molecular sieves. N,N-Dimethylformamide
(DMF) was stored over 3Å molecular sieves. All reactions sen-
sitive to oxygen or moisture were carried out under nitrogen
atmosphere using oven-dried glassware. All microwave irradia-
tion experiments were carried out in a dedicated CEM-Explorer
and CEM Discover monomode microwave apparatus, operating
at a frequency of 2.45GHz with continuous irradiation power
from 0 to 300W with utilization of the standard absorbance level
of 300W maximum power. The reactions were carried out in
10-mL glass tubes, sealed with a Teflon septum and placed in
the microwave cavity. Initially, microwave irradiation of required
watts was used, and the temperature was ramped from room tem-
perature to the desired temperature. Once this was reached the
reaction mixture was held at this temperature for the required
time. The reaction mixture was continuously stirred during the
reaction. The temperature was measured with an IR sensor on
the outer surface of the process vial. After the irradiation period,
gas jet cooling rapidly cooled the reaction vessel to ambient
temperature.
9-(2′,3′,4′,6′-Tetra-O-Acetyl-β-D-Glucopyranosyl)-
N6-Benzoyl Adenine (2)
Amixture of N6-benzoyladenine (797mg, 3.33mmol, 1.3 equiv),
hexamethyldisilazane (HMDS) (871µL, 4.13mmol, 1.24 equiv)
and saccharine (27mg, 0.15mmol, 0.046 equiv) in anhy-
drous CH3CN (14mL) was refluxed for 1 h under nitrogen.
1,2,3,4,6-Penta-O-acetyl-D-glucopyranose (1) (1 g, 2.56mmol)
and tin(IV) chloride (SnCl4) (419µL, 3.58mmol, 1.4 equiv) were
then added and the reaction mixture was stirring under reflux
for 2 more h, cooled, neutralized with aqueous sodium bicar-
bonate, and extracted with ethyl acetate (1000mL). The organic
extract was dried over anhydrous sodium sulfate, filtered, and
evaporated to dryness. The residue was purified by flash column
chromatography (EtOAc/ hexane 7:3) to give compound 2, as a
white solid (814mg, 56%); mp 169–171◦C; [α]22D = −6 (c 0.2,
CHCl3); Rf = 0.47 (EtOAc); λmax 280 nm (ε 20557); 1H NMR
(CDCl3,300MHz): δ 8.83 (s, 1H, H-2), 8.22 (s, 1H, H-8), 8.04-
7.51 (m, 5H, Bz), 5.98 (d, 1H, J1′,2′ = 9.4Hz, H-1′), 5.65 (t, 1H,
J = 9.3Hz, H-3′), 5.50 (t, 1H, J = 9.4Hz, H-2′), 5.32 (t, 1H, J =
9.7Hz, H-4′), 4.34 (dd, 1H, J5′,6a′ = 4.1Hz, J6a′,6b′ = 12.8Hz, H-
6a′), 4.24-4.14 (m, 1H, H-6b′), 4.11-4.02 (m, 1H, H-5′), 2.08, 2.07,
2.04, 1.79 (4s, 12H, 4OAc);13CNMR (CDCl3, 75.5MHz): δ 170.4,
169.8, 169.3, 169.0, 164.5, 152.0, 151.9, 149.5, 140.9, 133.1, 133.0,
128.9, 128.1, 122.2, 80.6, 75.2, 72.7, 70.3, 67.7, 61.5, 20.6, 20.5,
20.4, 20.1; Mass (M+H)+: 570.16; Anal. Calcd. for C26H27N5O10:
C, 54.83; H, 4.78; N, 12.30%. Found: C, 55.16; H, 4.66;
N, 12.53%.
9-(2′,3′,4′,6′-Tetra-O-Acetyl-β-D-Glucopyranosyl)-
8-Bromo-N6-Benzoyl Adenine (3)
To a solution of 9-(2′,3′,4′,6′-tetra-O-acetyl-β-D-
glucopyranosyl)-N6-benzoyl adenine (2) (250mg, 0.44mmol),
and sodium acetate (172 mg, 2.1mmol) in 1.6mL of glacial acetic
acid, 75µL, 1.45mmol of bromine were added. The reaction
was left to stir at room temperature until completion (14 h). The
whole was extracted with ethyl acetate and satured Na2S2O3.
The organic layer was washed with water and brine, dried over
anhydrous sodium sulfate, filtered, and evaporated to dryness.
The residue was purified by flash column chromatography
(EtOAc/ hexane 7:3) to give compound 3, (171mg, 60%);
[α]22D = −3 (c 0.2, CHCl3); Rf = 0.45 (EtOAc/ hexane 7:3);
λmax 282 nm (ε 21223); 1H NMR (CDCl3,300MHz): δ 8.82 (s,
1H, H-2), 8.04-7.49 (m, 5H, Bz), 6.21 (t, 1H, J = 9.6Hz, H-2′),
5.96 (d, 1H, J1′,2′ = 9.6Hz, H-1′), 5.47 (t, 1H, J = 9.4Hz,
H-3′), 5.35 (t, 1H, J = 9.9Hz, H-4′), 4.26-4.25 (m, 2H, H-6a′,
H-6b′), 4.06-3.96 (m, 1H, H-5′), 2.09, 2.07, 2.04, 1.79 (4s, 12H,
4OAc);13C NMR (CDCl3, 75.5MHz): δ 170.5, 170.0, 169.9,
169.3, 164.7, 153.3, 152.9, 149.2, 133.3, 131.0, 128.9, 128.6, 128.2,
122.3, 78.2, 72.9, 68.8, 67.6, 67.5, 61.5, 20.7, 20.6, 20.5, 20.2; Mass
(M+H)+: 648.08; Anal. Calcd. for C26H26BrN5O10: C, 48.16; H,
4.04; Br, 12.32; N, 10.80%. Found: C, 48.44; H, 4.15; Br, 12.11;
N, 10.99%.
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General Experimental Procedure for the
Preparation of Protected C8-Alkynyl
Adenine Pyranonucleosides (4a–e)
The appropriate alkynes (3 equiv), Pd(PPh3)4 (43mg, 0.1
equiv), CuI (7mg, 0.1 equiv), triethylamine (103µL, 2 equiv)
and 9-(2′,3′,4′,6′-tetra-O-acetyl-β-D-glucopyranosyl)-8-bromo-
N6-benzoyl adenine (3) (240mg, 0.37mmol), were irradiated
under microwaves (200W) in 1mL of anhydrous DMF for
10min at 120◦C. The reaction mixture was concentrated under
reduced pressure and the crude residue was purified by flash
chromatography on silica gel. The purified material was dried in
vacuo to afford the corresponding derivatives 4a–e, as colorless
foams.
9-(2′,3′,4′,6′-Tetra-O-Acetyl-β-D-Glucopyranosyl)-
8-Heptynyl-N6-Benzoyl Adenine (4a)
139mg, 56%; [α]22D = −4 (c 0.4, CHCl3); Rf = 0.10 (EtOAc/
hexane 6:4); λmax 303 nm (ε 22594); 1HNMR (CDCl3,300MHz):
δ 8.99 (br s, 1H, NH), 8.85 (s, 1H, H-2), 8.03-7.41 (m, 5H, Bz),
6.28 (t, 1H, J = 9.4Hz, H-2′), 5.95 (d, 1H, J1′,2′ = 9.2Hz, H-
1′), 5.46 (t, 1H, J = 9.3Hz, H-3′), 5.35 (t, 1H, J = 9.3Hz, H-4′),
4.28-4.19 (m, 2H, H-6a′, H-6b′), 4.04-3.87 (m, 1H, H-5′), 2.62 (t,
2H, J = 7.1Hz, α-CH2), 2.09, 2.08, 2.05, 1.78 (4s, 12H, 4OAc),
1.56-1.35 (m, 6H, 3 × CH2), 0.96 (t, 3H, J = 7.2Hz, CH3);13C
NMR (CDCl3, 75.5 MHz): δ 170.8, 170.5, 170.0, 169.8, 165.0,
153.5, 152.2, 151.3, 148.8, 134.9, 133.0, 129.2, 127.9, 119.9, 97.7,
94.5, 82.9, 70.8, 70.1, 67.5, 67.2, 63.7, 31.5, 31.2, 29.6, 22.3, 21.5,
21.3, 21.0, 20.9, 15.2; Mass (M+H)+: 664.26; Anal. Calcd. for
C33H37N5O10: C, 59.72; H, 5.62; N, 10.55%. Found: C, 59.96; H,
5.94; N, 10.65%.
9-(2′,3′,4′,6′-Tetra-O-Acetyl-β-D-Glucopyranosyl)-
8-Phenylethynyl-N6-Benzoyl Adenine (4b)
161mg, 66%; [α]22D = −6(c 0.4, CHCl3); Rf = 0.33 (CH2Cl2/
MeOH 9.8:0.2); λmax 300 nm (ε 29706); 1H NMR (CDCl3,
300MHz): δ 8.95 (br s, 1H, NH), 8.87 (s, 1H, H-2), 8.01-7.45
(m, 10H, Bz and Ph), 6.31 (t, 1H, J = 9.3Hz, H-2′), 6.10 (d,
1H, J1′,2′ = 9.4Hz, H-1′), 5.49 (t, 1H, J = 9.2Hz, H-3′), 5.35
(t, 1H, J = 9.5Hz, H-4′), 4.31-4.22 (m, 2H, H-6a′, H-6b′), 4.08-
3.98 (m, 1H, H-5′), 2.09, 2.05, 1.90, 1.77 (4s, 12H, 4OAc);13C
NMR (CDCl3, 75.5MHz): δ 170.6, 170.3, 169.9, 169.7, 165.3,
153.1, 152.4, 150.5, 148.5, 134.5, 133.8, 133.5, 129.9, 129.5, 129.0,
128.3, 123.6, 119.3, 102.6, 98.7, 87.3, 83.6, 70.5, 67.9, 67.5, 63.5,
21.5, 21.3, 20.9, 20.5; Mass (M+H)+: 670.18; Anal. Calcd. for
C34H31N5O10: C, 60.98; H, 4.67; N, 10.46%. Found: C, 61.23; H,
4.28; N, 10.80%.
9-(2′,3′,4′,6′-Tetra-O-Acetyl-β-D-Glucopyranosyl)-
8-p-Tolylethynyl-N6-Benzoyl Adenine (4c)
157mg, 61%; [α]22D = −10 (c 0.3, CHCl3); Rf = 0.37 (EtOAc/
hexane 8:2); λmax 325 nm (ε 27336); 1HNMR (CDCl3, 300MHz):
δ 8.98 (br s, 1H, NH), 8.86 (s, 1H, H-2), 8.02-7.29 (m, 9H, Bz and
ArH), 6.31 (t, 1H, J = 9.4Hz, H-2′), 6.08 (d, 1H, J1′,2′ = 9.3Hz,
H-1′), 5.48 (t, 1H, J = 9.4Hz, H-3′), 5.37 (t, 1H,J = 9.7Hz,
H-4′), 4.29-4.22 (m, 2H, H-6a′, H-6b′), 4.07-3.98 (m, 1H, H-5′),
2.43 (s, 3H, CH3), 2.09, 2.05, 1.91, 1.77 (4s, 12H, 4OAc);13CNMR
(CDCl3, 75.5MHz): δ 170.3, 170.1, 169.7, 169.3, 165.1, 153.2,
152.3, 150.7, 148.7, 139.5, 135.8, 133.7, 133.4, 129.6, 129.2, 128.8,
120.3, 120.1, 102.4, 98.3, 87.6, 83.5, 70.7, 67.5, 67.1, 63.7, 22.5,
21.7, 21.5, 21.0, 20.2; Mass (M+H)+: 684.22; Anal. Calcd. for
C35H33N5O10: C, 61.49; H, 4.87; N, 10.24%. Found: C, 61.84; H,
4.52; N, 10.02%.
9-(2′,3′,4′,6′-Tetra-O-Acetyl-β-D-Glucopyranosyl)-
8-(Pyridin-3-yl-Ethynyl)-N6-Benzoyl Adenine (4d)
141mg, 58%; [α]22D = −12 (c 0.2, CHCl3); Rf = 0.23 (EtOAc/
hexane 6:4); λmax 320 nm (ε 16156); 1HNMR (CDCl3, 300MHz):
δ 8.99 (br s, 1H, NH), 8.87 (s, 1H, H-2), 8.72-7.39 (m, 9H,
Bz and pyridine), 6.26 (t, 1H, J = 9.5Hz, H-2′), 6.11 (d, 1H,
J1′,2′ = 9.3Hz, H-1′), 5.48 (t, 1H, J = 9.3Hz, H-3′), 5.35 (t, 1H,
J = 9.7Hz, H-4′), 4.32 (dd, 1H,J5′,6a′= 4.7Hz, J6a′,6b′ = 12.5Hz,
H-6a′), 4.21 (dd, 1H,J5′,6b′ = 2.0Hz,J6a′,6b′ = 12.5Hz, H-6b′),
4.09-4.00 (m, 1H, H-5′), 2.09, 2.05, 1.94, 1.78 (4s, 12H, 4OAc);13C
NMR (CDCl3, 75.5 MHz): δ 170.4, 170.0, 169.6, 169.2, 165.4,
153.0, 152.7, 151.6, 150.7, 150.5, 148.8, 140.5, 135.4, 133.6, 129.5,
128.2, 124.6, 120.5, 117.1, 98.7, 95.6, 83.3, 75.7, 70.5, 67.5, 67.2,
63.5, 21.3, 21.0, 20.9, 20.7; Mass (M+H)+: 671.21; Anal. Calcd.
for C33H30N6O10: C, 59.10; H, 4.51; N, 12.53%. Found: C, 59.42;
H, 4.76; N, 12.22%.
9-(2′,3′,4′,6′-Tetra-O-Acetyl-β-D-Glucopyranosyl)-
8-(Pyridin-2-yl-Ethynyl)-N6-Benzoyl Adenine (4e)
127mg, 50%; [α]22D = −2 (c 0.1, CHCl3); Rf = 0.21 (EtOAc/ hex-
ane 7:3); λmax 315 nm (ε 22103); 1H NMR (CDCl3, 300MHz):
δ 8.80 (br s, 2H, NH, H-2), 8.07-7.35 (m, 9H, Bz and pyridine),
6.31 (t, 1H,J = 9.4Hz, H-2′), 6.12 (d, 1H, J1′,2′ = 9.3Hz, H-
1′), 5.71 (t, 1H, J = 9.5Hz, H-3′), 5.48 (t, 1H,J = 9.5Hz, H-4′),
4.29-4.25 (m, 2H, H-6a′, H-6b′), 4.10-4.02 (m, 1H, H-5′), 2.09,
2.03, 1.92, 1.75 (4s, 12H, 4OAc);13C NMR (CDCl3, 75.5MHz): δ
170.6, 170.3, 169.7, 169.5, 164.3, 153.2, 152.8, 151.5, 149.9, 148.3,
145.2, 139.5, 134.6, 132.7, 128.6, 127.8, 127.6, 123.7, 119.7, 95.7,
92.5, 84.8, 82.7, 72.8, 69.5, 68.3, 65.7, 21.0, 20.7, 20.6, 20.5; Mass
(M+H)+: 671.20; Anal. Calcd. for C33H30N6O10: C, 59.10; H,
4.51; N, 12.53%. Found: C, 59.40; H, 4.73; N, 12.34%.
General Procedure for the Preparation of
Unprotected C8-Alkynyl Adenine
Pyranonucleosides (5a–d)
The protected nucleosides 4a–e (0.5mmol), were treated with
methanolic ammonia (satured at 0◦C, 27.9mL). The solution
was stirred overnight at room temperature and then evaporated
under reduced pressure. The residue was purified by flash col-
umn chromatography to afford the unprotected derivatives 5a–d,
in 60–72% yields, as yellowish and white foams.
9-(β-D-Glucopyranosyl)-8-Heptynyl-Adenine (5a)
117mg, 60%; [α]22D = −2 (c 0.2, MeOH); Rf = 0.17 (EtOAc/
MeOH 8:2) λmax 292 nm (ε 19971); 1H NMR (DMSO-d6,
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300MHz): δ 8.15 (s, 1H, H-2), 7.24 (s, 2H, NH2), 5.43 (d, 1H,
J1′,2′ = 9.5Hz, H-1′), 5.16, 5.09, 5.00 (3br s, 3H, 3OH), 4.60-4.45
(m, 2H, OH, H-2′), 3.81-3.34 (m, 5H, H-3′, H-4′, H-5′, H-6a′,
H-6b′), 1.78-1.76 (m, 2H, β-CH2), 1.63 (t, 2H, J = 7.2Hz, α-
CH2), 1.51-1.30 (m, 4H, 2× CH2), 0.93 (t, 3H,J = 7.2Hz, CH3).
13C NMR (DMSO-d6, 75.5MHz): δ 156.8, 152.7, 150.1, 148.3,
119.9, 96.2, 93.9, 83.2, 78.8, 73.6, 70.5, 66.7, 65.4, 30.9, 29.2, 22.3,
19.0, 14.5; Mass (M+H)+: 392.20; Anal. Calcd. for C18H25N5O5:
C, 55.23; H, 6.44; N, 17.89%. Found: C, 54.90; H, 6.73;
N, 17.72%.
9-(β-D-Glucopyranosyl)-8-Phenylethynyl-
Adenine (5b)
143mg, 72%; [α]22D = -6 (c 0.1, MeOH); Rf = 0.30 (EtOAc/
MeOH 9:1); λmax 313 nm (ε 14209); 1H NMR (DMSO-d6, 300
MHz): δ 8.19 (s, 1H, H-2), 7.66 (br s, 2H, NH2), 7.61-7.47
(m, 5H, Ph), 5.55 (d, 1H, J1′,2′ = 9.2Hz, H-1′), 5.40 (d, 1H,
J = 5.3Hz, OH), 5.34 (d, 1H, J = 4.1Hz, OH), 5.21 (d, 1H,
J = 5.1Hz, OH), 4.70 (t, 1H, J= 4.4Hz, OH), 4.54-4.40 (m,
1H, H-2′), 3.81-3.39 (m, 5H, H-3′, H-4′, H-5′, H-6a′, H-6b′).
13C NMR (DMSO-d6, 75.5 MHz): δ 156.3, 152.6, 150.0, 148.1,
132.7, 128.9, 128.7, 123.0, 119.7, 101.9, 96.3, 86.8, 83.3, 78.1, 73.4,
70.8, 65.8; Mass (M+H)+: 398.15; Anal. Calcd. for C19H19N5O5:
C, 57.43; H, 4.82; N, 17.62%. Found: C, 57.81; H, 4.51;
N, 17.90%.
9-(β-D-Glucopyranosyl)-8-p-Tolylethynyl-
Adenine (5c)
140mg, 67%; [α]22D = −4 (c 0.1, MeOH); Rf = 0.21 (EtOAc/
MeOH 8:2); λmax 316 nm (ε 12871); 1H NMR (DMSO-d6,
300MHz): δ 8.18 (s, 1H, H-2), 7.55 (d, 2H,J = 8.1Hz, ArH),
7.37 (br s, 2H, NH2), 7.32 (d, 2H, J = 8.0Hz, ArH), 5.55 (d,
1H, J1′,2′ = 9.3Hz, H-1′), 5.25 (d, 1H, J= 4.1Hz, OH), 5.15,
5.04 (2br s, 2H, 2OH), 4.58-4.47 (m, 2H, OH, H-2′), 3.81-3.34
(m, 5H, H-3′, H-4′, H-5′, H-6a′, H-6b′), 2.38 (s, 3H, CH3). 13C
NMR (DMSO-d6, 75.5MHz): δ 156.4, 152.1, 150.4, 148.5, 138.5,
132.5, 129.0, 122.3, 120.2, 101.8, 96.0, 86.9, 83.0, 78.9, 73.5, 70.7,
65.6, 24.6; Mass (M+H)+: 412.17; Anal. Calcd. for C20H21N5O5:
C, 58.39; H, 5.14; N, 17.02%. Found: C, 58.72; H, 5.45;
N, 17.27%.
9-(β-D-Glucopyranosyl)-8-(Pyridin-3-yl-Ethynyl)-
Adenine (5d)
139 mg, 70%; [α]22D = +2 (c 0.2, MeOH); Rf = 0.16 (CH2Cl2/
MeOH 7:3); λmax 306 nm (ε 7353); 1H NMR (DMSO-d6,
300MHz): δ 8.89-8.68 (m, 2H, pyridine), 8.21 (s, 1H, H-2), 8.10-
7.52 (m, 2H, pyridine), 7.44 (br s, 2H, NH2), 5.58 (d, 1H, J1′,2′ =
9.3Hz, H-1′), 5.28, 5.07, 4.56 (3 br s, 3H, 3OH), 4.45 (t, 1H,J =
8.1Hz, OH), 3.81-3.40 (m, 6H, H-2′, H-3′, H-4′, H-5′, H-6a′,
H-6b′). 13C NMR (DMSO-d6, 75.5MHz): δ 156.9, 152.5, 152.3,
150.5, 149.8, 148.5, 139.9, 123.8, 119.8, 116.8, 96.0, 95.7, 83.1,
78.7, 74.1, 73.9, 70.2, 65.2; Mass (M+H)+: 399.15; Anal. Calcd. for
C18H18N6O5: C, 54.27; H, 4.55; N, 21.10%. Found: C, 54.62; H,
4.74; N, 21.38%.
8-Phenylethynyl-Adenine (II)
8-Bromoadenine (I) (43mg, 0.2mmol) was mixed with
anhydrous DMF (1mL), phenylacetylene (66µL, 3 equiv),
triethylamine (55µL, 2 equiv), Pd(PPh3)4 (23mg, 0.1 equiv),
CuI (11mg, 0.3 equiv) and irradiated with microwaves (200W)
for 6min at 60◦C. After removing volatiles in vacuo, the solid
residue was purified by flash chromatography (CH2Cl2/MeOH,
9.5:0.5) to provide compound II, as yellowish foam. 19mg,
40%; [α]22D = −2 (c 0.2, MeOH); Rf = 0.13 (CH2Cl2/ MeOH
8.5:1.5); λmax 308 nm (ε 9701); 1H NMR (DMSO-d6, 300 MHz):
δ 13.38 (br s, 1H, NH), 8.15 (s, 1H, H-2), 7.65-7.49 (m, 5H,
Ph), 7.27 (br s, 2H, NH2). 13C NMR (DMSO-d6, 75.5MHz):
δ 156.8, 154.2, 152.6, 148.1, 132.7, 129.1, 129.0, 123.0, 119.8,
101.8, 67.1; Mass (M+H)+: 236.08; Anal. Calcd. for C13H9N5:
C, 66.37; H, 3.86; N, 29.77%. Found: C, 66.59; H, 4.01; N,
29.40%.
Antiproliferative Assay
Compounds 4e, 5a–d, and II, were evaluated for their cyto-
static activity against human cervix carcinoma (HeLa) cells,
human lymphocytes (CEM) as well as murine leukemia (L1210)
cells. All assays were performed in 96-well microtiter plates.
To each well (5–7.5) × 104 tumor cells were added and vary-
ing concentrations of the test compounds ranging from 250,
50, 10, 2, 0.4, to 0.08µM. The tumor cells were allowed then
to proliferate at 37◦C in a humidified CO2-controlled atmo-
sphere. To obtain their optimal growth curves this is for 2 days
of the murine leukemia (L1210) cells and for 3 days for the
human lymphocytic (CEM) cells and the human cervix carci-
noma (HeLa) cells. At the end of the incubation period, the cells
were counted in a Coulter counter. The IC50 (50% inhibitory
concentration) was defined as the concentration of the com-
pound that inhibited cell proliferation by 50%. Experiments were
repeated at least three times and these data are presented in
Table 1.
Results and Discussion
Herein, we describe the synthesis of C8-alkynyl adenine pyra-
nonucleosides and present their biological properties. The
starting material of our synthesis was the commercially avail-
able per-O-acetylated D-glucose 1 which upon coupling, via
two-step Vorbrüggen method (Vorbrüggen and Höfle, 1981),
TABLE 1 | Cytostatic activity of the compounds against tumor cell (L1210,
CEM, and HeLa) proliferation.
Compound ICa
50
(µM)
L1210 CEM HeLa
4e 2.9 ± 0.0 1.2 ± 0.2 3.0 ± 0.7
5a >250 >250 >250
5b >250 >250 >250
5c >250 >250 >250
5d >250 >250 ≥250
II 5.9 ± 5.5 4.2 ± 0.8 10 ± 3.0
5-Fluorouracil 0.33 ± 0.17 18 ± 5 0.54 ± 0.12
a50% inhibitory concentration or compound concentration required to inhibit tumor cell
proliferation by 50%.
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with N6-benzoyl adenine, gave selectively the N9-isomeric
adenine nucleoside 2, under thermodynamically controlled con-
ditions (SnCl4/CH3CN, reflux). Trans rule was followed (Baker,
1957) and the β-configured nucleoside 2 was solely obtained as
deduced from 1H NMR vicinal coupling data (J1′,2′ = 9.4Hz).
Since halogenated C8-purine nucleosides have proven use-
ful intermediates for the efficient preparation of their cor-
responding C8-alkynyl derivatives (Agrofoglio et al., 2003),
the adenine nucleoside 2 was directly brominated after treat-
ment with Br2/AcOH/AcONa (Holmes and Robins, 1964),
affording the 8-bromo analog 3, in approximately 60% yield
after aqueous work-up and flash chromatography. The posi-
tion of substitution of the bromine atom was further con-
firmed by the absence of the characteristic sharp absorption
peak at 8.22 ppm due to H-8 of nucleoside 2, while the
syn conformation for adenine was induced due to the bulky
bromo substituent at C8 position (Sarma et al., 1974). 8-Alkynyl
adenine nucleosides 4 were accessed, through Sonogashira
cross-coupling reaction of intermediate 3 with several termi-
nal acetylenes, under microwave irradiation (200W) (Figure 1).
In a typical experiment, an effective catalyst (Pd(PPh3)4)/co-
catalyst (CuI) combination proved to be (1:1) ratio (Meneni
et al., 2007) affording 4a–e, in satisfactory yields (50–66%).
To provide a detailed structure-activity relationship studies,
diverse alkyne substituents R were selected which include lin-
ear alkyl chains (4a, R = n-pentyl), aromatic rings (4b, R =
phenyl, 4c, R= p-tolyl) and pyridine moieties (4d, R = 3-
pyridyl, 4e, R = 2-pyridyl). Finally, total deprotection of 4a–e
by the action of saturated methanolic ammonia afforded only
the target derivatives 5a–d, while attempts to remove all pro-
tecting groups from 4e either with sodium methoxide (Bozó
et al., 1998) or potassium carbonate-methanol (Plattner et al.,
1972) resulted in a mixture of intractable and inseparable
materials.
FIGURE 1 | Synthesis of C8-alkynyl adenine glucopyranonucleosides.
FIGURE 2 | Synthesis of 8-phenylethynyl-adenine.
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Based on the promising cytotoxic activity profile of our
prior synthesized C5-phenylethynyl uracil glucopyranonucleo-
side (Dimopoulou et al., 2013) and in order to explore the
impact of the glycosidic part on the biological activity as
well as the potential inhibitory effects of adenine moiety, we
sought to introduce phenylacetylene substituent in 8-position
of adenine itself. Therefore, we investigated the develop-
ment of the efficient Sonogashira alkynylation protocol for
the cross-coupling of commercially available 8-bromoadenine
(I) with phenylacetylene under microwave irradiation (200W)
(Figure 2). 8-Bromoadenine (I) was mixed with anhydrous
DMF, phenylacetylene, triethylamine, Pd(PPh3)4, CuI, irradi-
ated with microwaves for 6min at 60◦C and after remov-
ing volatiles in vacuo, the solid residue was purified by
flash chromatography to provide compound II, in acceptable
yield (40%).
Cytostatic Activity
The cytostatic activity of the novel C8-modified adenine pyra-
nonucleosides 4e, 5a–d as well as 8-phenylethynyl-adenine (II)
was determined against murine leukemia (L1210), human lym-
phocyte (CEM) and human cervix carcinoma (HeLa) cell cul-
tures (Table 1). Compounds 4e and II were less cytostatic than
5-fluorouracil (almost an order of magnitude) against murine
leukemia (L1210) and human cervix carcinoma (HeLa) cells,
while the same compounds proved to be more active than 5-
fluorouracil against human lymphocyte (CEM) cells.
Conclusion
In summary, we have prepared several novel C8-alkynyl adenine
nucleosides as well as 8-phenylethynyl-adenine, via Sonogashira
coupling conditions under microwave irradiation. Among the
compound series tested, the protected adenine pyranonucleoside
4e, as well as phenylethynyl adenine (II) showed significant cyto-
toxicity (IC50 of 1.2–10.0µM) against murine leukemia (L1210),
human lymphocyte (CEM) and human cervix carcinoma (HeLa)
cell cultures. Since the glucose derivative of phenylethynyl ade-
nine, nucleoside 5b, showed no activity, it is clear that it is stable
and not susceptible to hydrolysis. The replacement of glucose
with ribo, arabino, and deoxyribose moieties as well as the intro-
duction of functional substituents on the phenyl ring, such as
halogens, nitro or amino and alkyl groups, could be explored
in the future in an attempt to further increase the cytostatic
potential of these lead compounds.
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